SI-BONE (SIBN) Financials

$19.12 -0.59 (-2.99%)

Closing price 04:00 PM Eastern

Extended Trading

$19.11 -0.01 (-0.03%)

As of 04:20 PM Eastern

Annual Income Statements for SI-BONE

This table shows SI-BONE's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-31	-43	-61
Consolidated Net Income / (Loss)	-31	-43	-61
Net Income / (Loss) Continuing Operations	-31	-43	-61
Total Pre-Tax Income	-31	-43	-61
Total Operating Income	-35	-47	-60
Total Gross Profit	132	109	91
Total Revenue	167	139	106
Operating Revenue	167	139	106
Total Cost of Revenue	35	29	16
Operating Cost of Revenue	35	29	16
Total Operating Expenses	167	156	150
Selling, General & Admin Expense	34	31	29
Marketing Expense	117	110	108
Research & Development Expense	17	15	14
Total Other Income / (Expense), net	4.41	3.45	-1.52
Interest Expense	3.44	3.46	2.82
Interest & Investment Income	7.85	6.92	1.30
Other Gains / (Losses), net	-0.07	0.14	-0.13
Basic Earnings per Share	($0.75)	($1.13)	($1.79)
Weighted Average Basic Shares Outstanding	41.47M	38.43M	34.20M
Diluted Earnings per Share	($0.75)	($1.13)	($1.79)
Weighted Average Diluted Shares Outstanding	41.47M	38.43M	34.20M
Weighted Average Basic & Diluted Shares Outstanding	42.45M	41.06M	34.99M
Cash Dividends to Common per Share	$0.00	$0.00	-

This table shows SI-BONE's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-6.54	-4.50	-6.58	-8.94	-11	-11	-10	-11	-11	-11	-14
Consolidated Net Income / (Loss)	-6.54	-4.50	-6.58	-8.94	-11	-11	-10	-11	-11	-11	-14
Net Income / (Loss) Continuing Operations	-6.54	-4.50	-6.58	-8.94	-11	-11	-10	-11	-11	-11	-14
Total Pre-Tax Income	-6.54	-4.42	-6.58	-8.94	-11	-11	-10	-11	-11	-11	-14
Total Operating Income	-7.48	-5.49	-7.63	-10	-12	-13	-11	-12	-11	-11	-14
Total Gross Profit	38	39	32	32	30	29	27	27	27	27	22
Total Revenue	47	49	40	40	38	39	34	33	33	32	26
Operating Revenue	47	49	40	40	38	39	34	33	33	32	26
Total Cost of Revenue	9.60	10	8.44	8.39	8.00	10	7.04	6.32	5.92	5.09	4.17
Operating Cost of Revenue	9.60	10	8.44	8.39	8.00	10	7.04	6.32	5.92	5.09	4.17
Total Operating Expenses	45	44	40	42	42	41	38	39	38	38	36
Selling, General & Admin Expense	9.96	9.15	8.10	8.33	8.18	8.08	7.71	7.80	7.47	7.07	7.07
Marketing Expense	31	31	27	29	29	29	27	27	27	28	26
Research & Development Expense	4.53	3.87	3.99	4.35	4.35	4.16	3.92	3.66	3.29	3.48	3.09
Total Other Income / (Expense), net	0.94	1.08	1.05	1.14	1.14	1.38	1.15	0.76	0.17	0.25	-0.59
Interest Expense	0.66	0.80	0.88	0.88	0.88	0.89	0.88	0.85	0.84	0.88	0.76
Interest & Investment Income	1.59	1.78	1.94	2.02	2.11	2.23	2.17	1.58	0.93	0.75	0.35
Other Income / (Expense), net	0.01	-	-	0.00	-0.09	-	-0.14	0.03	0.07	-	-0.18
Basic Earnings per Share	($0.15)	($0.10)	($0.16)	($0.22)	($0.27)	($0.26)	($0.25)	($0.30)	($0.32)	($0.32)	($0.41)
Weighted Average Basic Shares Outstanding	42.34M	41.47M	41.72M	41.32M	40.93M	38.43M	40.27M	37.86M	34.92M	34.20M	34.36M
Diluted Earnings per Share	($0.15)	($0.10)	($0.16)	($0.22)	($0.27)	($0.26)	($0.25)	($0.30)	($0.32)	($0.32)	($0.41)
Weighted Average Diluted Shares Outstanding	42.34M	41.47M	41.72M	41.32M	40.93M	38.43M	40.27M	37.86M	34.92M	34.20M	34.36M
Weighted Average Basic & Diluted Shares Outstanding	42.61M	42.45M	41.94M	41.69M	41.20M	41.06M	40.50M	40.20M	35.18M	34.99M	34.50M

This table details how cash moves in and out of SI-BONE's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	1.68	13	-43
Net Cash From Operating Activities	-12	-19	-42
Net Cash From Continuing Operating Activities	-12	-19	-42
Net Income / (Loss) Continuing Operations	-31	-43	-61
Consolidated Net Income / (Loss)	-31	-43	-61
Depreciation Expense	4.38	5.43	3.45
Amortization Expense	-5.29	-3.80	0.43
Non-Cash Adjustments To Reconcile Net Income	30	28	24
Changes in Operating Assets and Liabilities, net	-10	-4.83	-7.96
Net Cash From Investing Activities	13	-60	-2.82
Net Cash From Continuing Investing Activities	13	-60	-2.82
Purchase of Property, Plant & Equipment	-10	-7.80	-9.51
Purchase of Investments	-205	-189	-120
Sale and/or Maturity of Investments	229	138	126
Net Cash From Financing Activities	1.96	91	2.20
Net Cash From Continuing Financing Activities	1.96	91	2.20
Repayment of Debt	-36	-35	0.00
Issuance of Debt	36	36	0.00
Issuance of Common Equity	2.15	86	1.82
Other Financing Activities, net	-0.15	4.39	0.38
Effect of Exchange Rate Changes	-0.48	0.13	-0.43
Cash Interest Paid	3.35	3.26	2.62

This table details how cash moves in and out of SI-BONE's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	6.24	4.72	4.65	-6.46	-1.23	-20	-57	88	2.25	-5.58	1.98
Net Cash From Operating Activities	-4.91	1.18	0.30	-6.33	-7.57	-2.30	-2.07	-3.59	-11	-6.78	-6.53
Net Cash From Continuing Operating Activities	-4.91	1.18	0.30	-6.33	-7.57	-2.30	-2.07	-3.59	-11	-6.78	-6.53
Net Income / (Loss) Continuing Operations	-6.54	-4.50	-6.58	-8.94	-11	-11	-10	-11	-11	-11	-14
Consolidated Net Income / (Loss)	-6.54	-4.50	-6.58	-8.94	-11	-11	-10	-11	-11	-11	-14
Depreciation Expense	1.28	1.21	1.09	0.99	1.09	1.57	1.53	1.24	1.09	1.00	0.95
Amortization Expense	-0.89	-1.16	-1.19	-1.42	-1.52	-1.55	-1.13	-0.59	-0.53	-0.35	0.16
Non-Cash Adjustments To Reconcile Net Income	7.44	7.59	7.08	7.35	7.50	8.23	6.81	6.36	6.43	6.32	6.00
Changes in Operating Assets and Liabilities, net	-6.20	-1.97	-0.09	-4.33	-3.74	0.44	0.73	0.61	-6.61	-2.57	0.53
Net Cash From Investing Activities	11	4.34	3.77	-1.83	6.35	-19	-55	2.28	12	0.09	8.73
Net Cash From Continuing Investing Activities	11	4.34	3.77	-1.83	6.35	-19	-55	2.28	12	0.09	8.73
Purchase of Property, Plant & Equipment	-2.07	-2.27	-3.04	-3.11	-2.08	-1.09	-1.41	-2.71	-2.58	-1.66	-3.57
Purchase of Investments	-47	-35	-61	-51	-59	-62	-78	-34	-16	-34	-30
Sale and/or Maturity of Investments	60	42	68	52	67	44	25	39	30	36	42
Net Cash From Financing Activities	0.10	-0.08	0.16	1.78	0.11	0.84	-0.24	89	1.21	0.69	0.11
Net Cash From Continuing Financing Activities	0.10	-0.08	0.16	1.78	0.11	0.84	-0.24	89	1.21	0.69	0.11
Other Financing Activities, net	0.10	-0.71	0.16	0.30	0.11	0.12	0.23	3.52	0.52	0.07	0.11
Effect of Exchange Rate Changes	0.42	-0.71	0.42	-0.08	-0.11	0.15	-0.14	0.03	0.10	0.41	-0.33

This table presents SI-BONE's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	230	230	158
Total Current Assets	208	211	138
Cash & Equivalents	35	33	21
Short-Term Investments	115	133	77
Accounts Receivable	27	22	21
Inventories, net	27	20	17
Prepaid Expenses	3.20	3.17	2.37
Plant, Property, & Equipment, net	20	16	16
Total Noncurrent Assets	2.28	3.03	4.38
Other Noncurrent Operating Assets	2.28	3.03	4.38
Total Liabilities & Shareholders' Equity	230	230	158
Total Liabilities	63	61	59
Total Current Liabilities	27	23	21
Accounts Payable	6.49	4.59	6.28
Accrued Expenses	19	17	14
Other Current Liabilities	1.15	1.42	1.39
Total Noncurrent Liabilities	36	38	38
Long-Term Debt	35	36	35
Capital Lease Obligations	0.88	1.51	2.87
Other Noncurrent Operating Liabilities	0.01	0.02	0.03
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	167	169	98
Total Preferred & Common Equity	167	169	98
Preferred Stock	0.00	0.00	0.00
Total Common Equity	167	169	98
Common Stock	598	569	455
Retained Earnings	-431	-400	-357
Accumulated Other Comprehensive Income / (Loss)	0.24	0.34	0.23

This table presents SI-BONE's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	227	227	224	224	231	234	149	158
Total Current Assets	204	204	202	204	211	213	128	139
Cash & Equivalents	41	30	26	32	53	111	23	26
Short-Term Investments	103	121	126	126	113	59	63	78
Accounts Receivable	27	25	25	22	20	20	23	16
Inventories, net	30	26	23	21	22	21	18	17
Prepaid Expenses	2.70	2.45	2.78	2.65	1.94	2.14	2.05	1.79
Plant, Property, & Equipment, net	21	21	19	17	16	18	17	14
Total Noncurrent Assets	2.00	2.55	2.40	2.74	3.37	3.71	4.05	4.64
Other Noncurrent Operating Assets	2.00	2.55	2.40	2.74	3.37	3.71	4.05	4.64
Total Liabilities & Shareholders' Equity	227	227	224	224	231	234	149	158
Total Liabilities	60	62	59	58	57	56	55	55
Total Current Liabilities	24	25	22	21	19	18	17	19
Accounts Payable	7.71	7.32	7.18	7.66	4.42	6.16	5.33	4.61
Accrued Expenses	15	16	13	12	14	11	9.90	11
Other Current Liabilities	1.09	1.21	1.38	1.43	1.40	1.40	1.40	1.34
Total Noncurrent Liabilities	36	37	37	37	38	38	38	37
Long-Term Debt	35	36	36	36	36	36	36	34
Capital Lease Obligations	0.58	1.14	0.89	1.19	1.87	2.21	2.53	3.18
Other Noncurrent Operating Liabilities	0.00	0.01	0.01	0.02	0.02	0.02	0.03	0.03
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	167	165	165	166	174	177	94	103
Total Preferred & Common Equity	167	165	165	166	174	177	94	103
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	167	165	165	166	174	177	94	103
Common Stock	605	591	585	577	563	557	462	449
Retained Earnings	-438	-427	-420	-411	-389	-379	-368	-346
Accumulated Other Comprehensive Income / (Loss)	0.32	0.58	0.23	0.27	0.36	0.30	0.30	0.16

This table displays calculated financial ratios and metrics derived from SI-BONE's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	20.37%	30.52%	18.03%
EBITDA Growth	20.19%	18.71%	-16.77%
EBIT Growth	24.89%	21.27%	-15.99%
NOPAT Growth	24.89%	21.27%	-15.36%
Net Income Growth	28.67%	29.25%	-8.28%
EPS Growth	33.63%	36.87%	-4.68%
Operating Cash Flow Growth	33.60%	55.08%	-5.37%
Free Cash Flow Firm Growth	-6.52%	35.92%	-7.62%
Invested Capital Growth	30.10%	4.81%	46.93%
Revenue Q/Q Growth	6.46%	5.23%	6.74%
EBITDA Q/Q Growth	16.30%	-4.73%	4.69%
EBIT Q/Q Growth	16.59%	-3.12%	4.84%
NOPAT Q/Q Growth	16.59%	-2.65%	4.24%
Net Income Q/Q Growth	17.35%	0.44%	5.11%
EPS Q/Q Growth	17.58%	5.04%	6.28%
Operating Cash Flow Q/Q Growth	21.86%	19.31%	12.48%
Free Cash Flow Firm Q/Q Growth	-1.83%	12.50%	13.87%
Invested Capital Q/Q Growth	3.44%	-8.50%	5.43%
Profitability Metrics	-	-	-
Gross Margin	79.03%	78.78%	85.24%
EBITDA Margin	-21.63%	-32.62%	-52.37%
Operating Margin	-21.08%	-33.79%	-56.02%
EBIT Margin	-21.08%	-33.79%	-56.02%
Profit (Net Income) Margin	-18.49%	-31.20%	-57.57%
Tax Burden Percent	100.24%	99.68%	100.22%
Interest Burden Percent	87.49%	92.64%	102.54%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-52.39%	-82.14%	-127.15%
ROIC Less NNEP Spread (ROIC-NNEP)	-47.24%	-70.97%	-103.77%
Return on Net Nonoperating Assets (RNNOA)	34.01%	49.76%	74.51%
Return on Equity (ROE)	-18.38%	-32.38%	-52.64%
Cash Return on Invested Capital (CROIC)	-78.56%	-86.84%	-165.16%
Operating Return on Assets (OROA)	-15.30%	-24.19%	-34.25%
Return on Assets (ROA)	-13.42%	-22.34%	-35.20%
Return on Common Equity (ROCE)	-18.38%	-32.38%	-52.64%
Return on Equity Simple (ROE_SIMPLE)	-18.51%	-25.59%	-62.31%
Net Operating Profit after Tax (NOPAT)	-25	-33	-42
NOPAT Margin	-14.76%	-23.65%	-39.21%
Net Nonoperating Expense Percent (NNEP)	-5.15%	-11.17%	-23.38%
Return On Investment Capital (ROIC_SIMPLE)	-12.14%	-15.87%	-30.60%
Cost of Revenue to Revenue	20.97%	21.22%	14.76%
SG&A Expenses to Revenue	20.19%	22.37%	27.22%
R&D to Revenue	9.91%	10.82%	12.81%
Operating Expenses to Revenue	100.11%	112.58%	141.26%
Earnings before Interest and Taxes (EBIT)	-35	-47	-60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-36	-45	-56
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.52	5.02	4.77
Price to Tangible Book Value (P/TBV)	3.52	5.02	4.77
Price to Revenue (P/Rev)	3.52	6.12	4.41
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.91	17.63	10.50
Enterprise Value to Revenue (EV/Rev)	2.84	5.20	3.85
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.22	0.22	0.39
Long-Term Debt to Equity	0.22	0.22	0.39
Financial Leverage	-0.72	-0.70	-0.72
Leverage Ratio	1.37	1.45	1.50
Compound Leverage Factor	1.20	1.34	1.53
Debt to Total Capital	17.87%	18.16%	27.90%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	17.87%	18.16%	27.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	82.13%	81.84%	72.10%
Debt to EBITDA	-1.00	-0.83	-0.68
Net Debt to EBITDA	3.15	2.84	1.06
Long-Term Debt to EBITDA	-1.00	-0.83	-0.68
Debt to NOPAT	-1.47	-1.14	-0.91
Net Debt to NOPAT	4.61	3.91	1.42
Long-Term Debt to NOPAT	-1.47	-1.14	-0.91
Altman Z-Score	4.10	6.83	1.89
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.66	9.01	6.50
Quick Ratio	6.54	8.01	5.57
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-37	-35	-54
Operating Cash Flow to CapEx	-118.37%	-239.94%	-438.15%
Free Cash Flow to Firm to Interest Expense	-10.75	-10.03	-19.23
Operating Cash Flow to Interest Expense	-3.61	-5.41	-14.78
Operating Cash Flow Less CapEx to Interest Expense	-6.66	-7.66	-18.15
Efficiency Ratios	-	-	-
Asset Turnover	0.73	0.72	0.61
Accounts Receivable Turnover	6.77	6.52	6.09
Inventory Turnover	1.48	1.57	1.09
Fixed Asset Turnover	9.19	8.80	8.67
Accounts Payable Turnover	6.33	5.42	3.31
Days Sales Outstanding (DSO)	53.94	56.01	59.89
Days Inventory Outstanding (DIO)	246.35	232.45	334.44
Days Payable Outstanding (DPO)	57.66	67.31	110.13
Cash Conversion Cycle (CCC)	242.64	221.16	284.20
Capital & Investment Metrics	-	-	-
Invested Capital	53	41	39
Invested Capital Turnover	3.55	3.47	3.24
Increase / (Decrease) in Invested Capital	12	1.88	12
Enterprise Value (EV)	474	722	410
Market Capitalization	588	850	469
Book Value per Share	$3.98	$4.18	$2.85
Tangible Book Value per Share	$3.98	$4.18	$2.85
Total Capital	203	207	136
Total Debt	36	38	38
Total Long-Term Debt	36	38	38
Net Debt	-114	-128	-59
Capital Expenditures (CapEx)	10	7.80	9.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)	31	22	19
Debt-free Net Working Capital (DFNWC)	181	188	116
Net Working Capital (NWC)	181	188	116
Net Nonoperating Expense (NNE)	6.24	10	20
Net Nonoperating Obligations (NNO)	-114	-128	-59
Total Depreciation and Amortization (D&A)	-0.91	1.63	3.88
Debt-free, Cash-free Net Working Capital to Revenue	18.31%	15.78%	17.99%
Debt-free Net Working Capital to Revenue	108.06%	135.32%	109.42%
Net Working Capital to Revenue	108.06%	135.32%	109.42%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.75)	($1.13)	($1.79)
Adjusted Weighted Average Basic Shares Outstanding	41.47M	38.43M	34.20M
Adjusted Diluted Earnings per Share	($0.75)	($1.13)	($1.79)
Adjusted Weighted Average Diluted Shares Outstanding	41.47M	38.43M	34.20M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	42.45M	41.06M	34.99M
Normalized Net Operating Profit after Tax (NOPAT)	-25	-33	-42
Normalized NOPAT Margin	-14.76%	-23.65%	-39.21%
Pre Tax Income Margin	-18.45%	-31.30%	-57.44%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-10.25	-13.56	-21.15
NOPAT to Interest Expense	-7.17	-9.49	-14.80
EBIT Less CapEx to Interest Expense	-13.30	-15.81	-24.52
NOPAT Less CapEx to Interest Expense	-10.22	-11.74	-18.17
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from SI-BONE's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	24.88%	26.10%	18.60%	20.01%	15.77%	21.61%	28.68%	30.17%	45.76%	26.65%	18.60%
EBITDA Growth	43.65%	56.41%	29.01%	7.06%	-17.80%	-17.29%	13.75%	33.23%	32.97%	18.15%	-3.01%
EBIT Growth	38.43%	56.07%	32.52%	15.61%	-8.17%	-10.73%	17.72%	33.78%	33.70%	19.00%	-3.70%
NOPAT Growth	37.89%	56.07%	31.66%	15.76%	-6.64%	-10.73%	17.67%	33.10%	33.05%	18.93%	-2.78%
Net Income Growth	40.00%	59.07%	34.39%	20.23%	1.99%	1.72%	29.21%	39.47%	36.10%	22.81%	10.80%
EPS Growth	44.44%	61.54%	36.00%	26.67%	15.63%	18.75%	39.02%	44.44%	38.46%	27.27%	14.58%
Operating Cash Flow Growth	35.13%	151.28%	114.57%	-76.43%	29.59%	66.10%	68.24%	75.81%	20.42%	46.71%	29.89%
Free Cash Flow Firm Growth	-173.84%	-52.06%	22.03%	42.99%	70.57%	47.83%	46.25%	35.67%	9.62%	14.89%	-64.40%
Invested Capital Growth	30.88%	30.10%	15.09%	8.82%	-3.10%	4.81%	20.76%	31.82%	51.72%	46.93%	109.42%
Revenue Q/Q Growth	-3.49%	21.47%	0.93%	5.55%	-2.55%	14.24%	2.13%	1.83%	2.36%	20.89%	3.31%
EBITDA Q/Q Growth	-30.14%	29.71%	26.26%	16.47%	-2.19%	-14.46%	3.44%	-5.88%	-2.66%	15.83%	25.25%
EBIT Q/Q Growth	-36.00%	28.02%	24.23%	16.99%	1.50%	-10.56%	5.24%	-6.41%	-1.59%	17.86%	23.73%
NOPAT Q/Q Growth	-36.15%	28.02%	24.26%	16.32%	3.70%	-11.97%	6.64%	-5.93%	0.01%	16.75%	24.13%
Net Income Q/Q Growth	-45.54%	31.64%	26.45%	18.02%	0.72%	-9.59%	10.57%	-0.73%	0.45%	21.07%	23.52%
EPS Q/Q Growth	-50.00%	37.50%	27.27%	18.52%	-3.85%	-4.00%	16.67%	6.25%	0.00%	21.95%	24.07%
Operating Cash Flow Q/Q Growth	-516.89%	290.07%	104.77%	16.34%	-229.60%	-10.81%	42.26%	66.61%	-58.72%	-3.80%	56.02%
Free Cash Flow Firm Q/Q Growth	-18.37%	-33.70%	-8.67%	-59.24%	34.27%	31.44%	20.55%	17.78%	-16.49%	29.36%	4.92%
Invested Capital Q/Q Growth	10.63%	3.44%	2.47%	11.61%	9.97%	-8.50%	-3.11%	-0.62%	18.95%	5.43%	5.77%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	79.71%	79.13%	79.09%	79.00%	78.87%	73.80%	79.30%	81.03%	81.89%	84.07%	84.23%
EBITDA Margin	-14.97%	-11.10%	-19.19%	-26.26%	-33.18%	-32.12%	-32.06%	-33.91%	-32.61%	-33.31%	-47.83%
Operating Margin	-15.82%	-11.21%	-18.92%	-25.21%	-31.80%	-32.18%	-32.84%	-35.92%	-34.53%	-35.35%	-51.32%
EBIT Margin	-15.80%	-11.21%	-18.92%	-25.20%	-32.05%	-32.18%	-33.26%	-35.84%	-34.30%	-35.35%	-52.02%
Profit (Net Income) Margin	-13.83%	-9.17%	-16.30%	-22.36%	-28.80%	-28.26%	-29.46%	-33.65%	-34.01%	-34.97%	-53.56%
Tax Burden Percent	100.00%	101.79%	99.91%	100.00%	100.00%	98.73%	100.00%	100.00%	100.00%	101.20%	100.00%
Interest Burden Percent	87.55%	80.38%	86.22%	88.73%	89.85%	88.95%	88.60%	93.87%	99.16%	97.78%	102.97%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-37.63%	-27.86%	-43.23%	-55.18%	-70.12%	-78.23%	-74.19%	-77.05%	-73.17%	-80.23%	-130.87%
ROIC Less NNEP Spread (ROIC-NNEP)	-36.49%	-27.33%	-42.22%	-53.65%	-67.17%	-75.86%	-71.93%	-74.31%	-68.55%	-76.31%	-126.01%
Return on Net Nonoperating Assets (RNNOA)	25.09%	19.67%	30.22%	38.53%	43.49%	53.19%	50.65%	53.38%	44.13%	54.79%	98.02%
Return on Equity (ROE)	-12.54%	-8.19%	-13.01%	-16.65%	-26.62%	-25.04%	-23.54%	-23.67%	-29.04%	-25.44%	-32.85%
Cash Return on Invested Capital (CROIC)	-68.08%	-78.56%	-75.52%	-74.95%	-69.83%	-86.84%	-97.08%	-110.42%	-139.24%	-165.16%	-229.94%
Operating Return on Assets (OROA)	-12.37%	-8.13%	-12.98%	-16.60%	-24.77%	-23.04%	-22.56%	-22.30%	-24.56%	-21.61%	-29.44%
Return on Assets (ROA)	-10.83%	-6.66%	-11.18%	-14.73%	-22.25%	-20.24%	-19.99%	-20.93%	-24.35%	-21.38%	-30.32%
Return on Common Equity (ROCE)	-12.54%	-8.19%	-13.01%	-16.65%	-26.62%	-25.04%	-23.54%	-23.67%	-29.04%	-25.44%	-32.85%
Return on Equity Simple (ROE_SIMPLE)	-15.87%	0.00%	-22.67%	-24.80%	-26.05%	0.00%	-25.07%	-26.87%	-58.51%	0.00%	-62.78%
Net Operating Profit after Tax (NOPAT)	-5.24	-3.85	-5.34	-7.05	-8.43	-8.75	-7.82	-8.37	-7.91	-7.91	-9.50
NOPAT Margin	-11.07%	-7.85%	-13.25%	-17.65%	-22.26%	-22.53%	-22.99%	-25.14%	-24.17%	-24.74%	-35.93%
Net Nonoperating Expense Percent (NNEP)	-1.14%	-0.54%	-1.02%	-1.53%	-2.94%	-2.38%	-2.26%	-2.74%	-4.62%	-3.91%	-4.86%
Return On Investment Capital (ROIC_SIMPLE)	-2.58%	-1.89%	-	-	-	-4.23%	-	-	-	-5.80%	-
Cost of Revenue to Revenue	20.29%	20.87%	20.91%	21.00%	21.13%	26.21%	20.70%	18.97%	18.11%	15.93%	15.77%
SG&A Expenses to Revenue	21.06%	18.68%	20.07%	20.85%	21.59%	20.80%	22.67%	23.43%	22.85%	22.12%	26.76%
R&D to Revenue	9.59%	7.90%	9.90%	10.89%	11.47%	10.71%	11.52%	10.98%	10.06%	10.89%	11.69%
Operating Expenses to Revenue	95.53%	90.35%	98.01%	104.22%	110.67%	105.98%	112.14%	116.95%	116.41%	119.42%	135.56%
Earnings before Interest and Taxes (EBIT)	-7.47	-5.49	-7.63	-10	-12	-13	-11	-12	-11	-11	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.08	-5.44	-7.74	-10	-13	-12	-11	-11	-11	-11	-13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.56	3.52	3.53	3.23	4.01	5.02	4.92	5.35	7.32	4.77	5.82
Price to Tangible Book Value (P/TBV)	3.56	3.52	3.53	3.23	4.01	5.02	4.92	5.35	7.32	4.77	5.82
Price to Revenue (P/Rev)	3.37	3.52	3.71	3.54	4.60	6.12	6.47	7.63	5.90	4.41	6.01
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.27	8.91	9.12	8.33	12.05	17.63	16.21	17.72	13.79	10.50	14.39
Enterprise Value to Revenue (EV/Rev)	2.76	2.84	2.99	2.78	3.77	5.20	5.49	6.58	5.49	3.85	5.35
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.22	0.22	0.23	0.22	0.23	0.22	0.22	0.22	0.41	0.39	0.37
Long-Term Debt to Equity	0.22	0.22	0.23	0.22	0.23	0.22	0.22	0.22	0.41	0.39	0.36
Financial Leverage	-0.69	-0.72	-0.72	-0.72	-0.65	-0.70	-0.70	-0.72	-0.64	-0.72	-0.78
Leverage Ratio	1.36	1.37	1.35	1.34	1.44	1.45	1.41	1.39	1.51	1.50	1.43
Compound Leverage Factor	1.19	1.10	1.17	1.19	1.29	1.29	1.25	1.30	1.49	1.46	1.47
Debt to Total Capital	17.74%	17.87%	18.45%	18.36%	18.39%	18.16%	17.91%	17.71%	29.05%	27.90%	27.14%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.03%
Long-Term Debt to Total Capital	17.74%	17.87%	18.45%	18.36%	18.39%	18.16%	17.91%	17.71%	29.05%	27.90%	26.11%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	82.26%	82.13%	81.55%	81.64%	81.61%	81.84%	82.09%	82.29%	70.95%	72.10%	72.86%
Debt to EBITDA	-1.17	-1.00	-0.86	-0.80	-0.79	-0.83	-0.88	-0.85	-0.76	-0.68	-0.66
Net Debt to EBITDA	3.52	3.15	2.63	2.47	2.56	2.84	2.98	2.92	0.94	1.06	1.13
Long-Term Debt to EBITDA	-1.17	-1.00	-0.86	-0.80	-0.79	-0.83	-0.88	-0.85	-0.76	-0.68	-0.63
Debt to NOPAT	-1.68	-1.47	-1.26	-1.16	-1.12	-1.14	-1.18	-1.13	-1.02	-0.91	-0.88
Net Debt to NOPAT	5.04	4.61	3.84	3.57	3.61	3.91	4.03	3.90	1.26	1.42	1.51
Long-Term Debt to NOPAT	-1.68	-1.47	-1.26	-1.16	-1.12	-1.14	-1.18	-1.13	-1.02	-0.91	-0.85
Altman Z-Score	4.88	4.52	4.53	4.27	5.71	7.32	7.99	9.18	5.47	2.90	4.68
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.53	7.66	8.25	9.17	9.76	9.01	10.89	11.68	7.72	6.50	7.50
Quick Ratio	7.14	6.54	7.12	7.99	8.63	8.01	9.64	10.43	6.53	5.57	6.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-19	-16	-12	-11	-6.99	-11	-16	-20	-24	-20	-29
Operating Cash Flow to CapEx	-237.02%	51.99%	9.95%	-203.47%	-363.64%	-210.16%	-146.71%	-132.28%	-416.94%	-408.13%	-182.73%
Free Cash Flow to Firm to Interest Expense	-28.91	-20.34	-13.68	-12.65	-7.93	-11.95	-17.54	-22.96	-28.33	-23.13	-38.21
Operating Cash Flow to Interest Expense	-7.42	1.48	0.34	-7.20	-8.59	-2.58	-2.35	-4.22	-12.83	-7.69	-8.65
Operating Cash Flow Less CapEx to Interest Expense	-10.55	-1.37	-3.09	-10.74	-10.96	-3.81	-3.94	-7.42	-15.91	-9.57	-13.38
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.78	0.73	0.69	0.66	0.77	0.72	0.68	0.62	0.72	0.61	0.57
Accounts Receivable Turnover	7.24	6.77	7.00	6.67	6.44	6.52	7.24	7.00	6.61	6.09	6.86
Inventory Turnover	1.43	1.48	1.46	1.54	1.62	1.57	1.24	1.16	1.15	1.09	1.03
Fixed Asset Turnover	9.19	9.19	8.43	8.22	8.48	8.80	8.53	8.19	8.67	8.67	8.92
Accounts Payable Turnover	4.77	6.33	5.97	5.04	4.86	5.42	5.40	3.81	3.61	3.31	3.20
Days Sales Outstanding (DSO)	50.44	53.94	52.18	54.76	56.64	56.01	50.39	52.14	55.19	59.89	53.22
Days Inventory Outstanding (DIO)	256.09	246.35	249.41	237.66	224.71	232.45	293.44	314.35	318.05	334.44	353.47
Days Payable Outstanding (DPO)	76.52	57.66	61.18	72.40	75.17	67.31	67.64	95.91	101.10	110.13	114.16
Cash Conversion Cycle (CCC)	230.02	242.64	240.41	220.02	206.18	221.16	276.19	270.58	272.14	284.20	292.53
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	59	53	51	50	45	41	45	46	46	39	37
Invested Capital Turnover	3.40	3.55	3.26	3.13	3.15	3.47	3.23	3.06	3.03	3.24	3.64
Increase / (Decrease) in Invested Capital	14	12	6.75	4.07	-1.44	1.88	7.69	11	16	12	19
Enterprise Value (EV)	487	474	469	418	542	722	725	818	641	410	533
Market Capitalization	596	588	583	533	663	850	854	949	688	469	599
Book Value per Share	$3.94	$3.98	$3.96	$4.00	$4.04	$4.18	$4.32	$5.04	$2.69	$2.85	$3.00
Tangible Book Value per Share	$3.94	$3.98	$3.96	$4.00	$4.04	$4.18	$4.32	$5.04	$2.69	$2.85	$3.00
Total Capital	203	203	202	202	203	207	211	216	132	136	141
Total Debt	36	36	37	37	37	38	38	38	38	38	38
Total Long-Term Debt	36	36	37	37	37	38	38	38	38	38	37
Net Debt	-108	-114	-113	-114	-121	-128	-129	-131	-48	-59	-66
Capital Expenditures (CapEx)	2.07	2.27	3.04	3.11	2.08	1.09	1.41	2.71	2.58	1.66	3.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)	36	31	28	29	25	22	25	25	26	19	18
Debt-free Net Working Capital (DFNWC)	180	181	179	180	183	188	192	194	112	116	122
Net Working Capital (NWC)	180	181	179	180	183	188	192	194	112	116	121
Net Nonoperating Expense (NNE)	1.31	0.65	1.23	1.88	2.47	2.23	2.20	2.83	3.22	3.27	4.66
Net Nonoperating Obligations (NNO)	-108	-114	-113	-114	-121	-128	-129	-131	-48	-59	-66
Total Depreciation and Amortization (D&A)	0.39	0.05	-0.11	-0.42	-0.43	0.02	0.41	0.64	0.55	0.65	1.11
Debt-free, Cash-free Net Working Capital to Revenue	20.29%	18.31%	17.96%	19.07%	17.32%	15.78%	18.86%	20.02%	22.12%	17.99%	18.05%
Debt-free Net Working Capital to Revenue	102.07%	108.06%	114.00%	119.62%	126.88%	135.32%	145.21%	156.22%	95.80%	109.42%	122.46%
Net Working Capital to Revenue	102.07%	108.06%	114.00%	119.62%	126.88%	135.32%	145.21%	156.22%	95.80%	109.42%	121.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.15)	($0.10)	($0.16)	($0.22)	($0.27)	($0.26)	($0.25)	($0.30)	($0.32)	($0.32)	($0.41)
Adjusted Weighted Average Basic Shares Outstanding	42.34M	41.47M	41.72M	41.32M	40.93M	38.43M	40.27M	37.86M	34.92M	34.20M	34.36M
Adjusted Diluted Earnings per Share	($0.15)	($0.10)	($0.16)	($0.22)	($0.27)	($0.26)	($0.25)	($0.30)	($0.32)	($0.32)	($0.41)
Adjusted Weighted Average Diluted Shares Outstanding	42.34M	41.47M	41.72M	41.32M	40.93M	38.43M	40.27M	37.86M	34.92M	34.20M	34.36M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	42.61M	42.45M	41.94M	41.69M	41.20M	41.06M	40.50M	40.20M	35.18M	34.99M	34.50M
Normalized Net Operating Profit after Tax (NOPAT)	-5.24	-3.85	-5.34	-7.05	-8.43	-8.75	-7.82	-8.37	-7.91	-7.91	-9.50
Normalized NOPAT Margin	-11.07%	-7.85%	-13.25%	-17.65%	-22.26%	-22.53%	-22.99%	-25.14%	-24.17%	-24.74%	-35.93%
Pre Tax Income Margin	-13.83%	-9.01%	-16.31%	-22.36%	-28.80%	-28.63%	-29.46%	-33.65%	-34.01%	-34.56%	-53.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-11.29	-6.91	-8.63	-11.45	-13.78	-14.05	-12.80	-14.04	-13.39	-12.82	-18.21
NOPAT to Interest Expense	-7.91	-4.84	-6.04	-8.02	-9.57	-9.84	-8.84	-9.85	-9.43	-8.97	-12.58
EBIT Less CapEx to Interest Expense	-14.42	-9.76	-12.07	-14.99	-16.14	-15.28	-14.39	-17.24	-16.47	-14.70	-22.94
NOPAT Less CapEx to Interest Expense	-11.04	-7.69	-9.48	-11.55	-11.93	-11.06	-10.44	-13.04	-12.51	-10.86	-17.31
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About SI-BONE's Financials

When does SI-BONE's financial year end?

According to the most recent income statement we have on file, SI-BONE's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has SI-BONE's net income changed over the last 2 years?

SI-BONE's net income appears to be on a downward trend, with a most recent value of -$30.91 million in 2024, falling from -$61.26 million in 2022. The previous period was -$43.34 million in 2023. Check out SI-BONE's forecast to explore projected trends and price targets.

What is SI-BONE's operating income?

SI-BONE's total operating income in 2024 was -$35.25 million, based on the following breakdown:

Total Gross Profit: $132.12 million
Total Operating Expenses: $167.37 million

How has SI-BONE revenue changed over the last 2 years?

Over the last 2 years, SI-BONE's total revenue changed from $106.41 million in 2022 to $167.18 million in 2024, a change of 57.1%.

How much debt does SI-BONE have?

SI-BONE's total liabilities were at $63.47 million at the end of 2024, a 4.0% increase from 2023, and a 7.1% increase since 2022.

How much cash does SI-BONE have?

In the past 2 years, SI-BONE's cash and equivalents has ranged from $20.72 million in 2022 to $34.95 million in 2024, and is currently $34.95 million as of their latest financial filing in 2024.

How has SI-BONE's book value per share changed over the last 2 years?

Over the last 2 years, SI-BONE's book value per share changed from 2.85 in 2022 to 3.98 in 2024, a change of 39.7%.

Related Companies

This page (NASDAQ:SIBN) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SI-BONE (SIBN) Financials

Frequently Asked Questions About SI-BONE's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SI-BONE (SIBN) Financials

Annual Income Statements for SI-BONE

Quarterly Income Statements for SI-BONE

Annual Cash Flow Statements for SI-BONE

Quarterly Cash Flow Statements for SI-BONE

Annual Balance Sheets for SI-BONE

Quarterly Balance Sheets for SI-BONE

Annual Metrics And Ratios for SI-BONE

Quarterly Metrics And Ratios for SI-BONE

Frequently Asked Questions About SI-BONE's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools